Blohmer J-U, Link T, Kummel S, Untch M, et al.

The authors conclude that: The results of the primary endpoints and selected secondary endpoints will be presented at the meeting.

[GS3-02] Durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: Results from phase II randomized trial SAFIR02-IMMUNO

Dalenc F, Garberis I, Filleron T, Lusque A, et al.

The authors conclude that: This is the first randomized trial comparing aPDL1 inhibitor to chemotherapy in the maintenance setting and to address the question of the efficacy of aPDL1i in HR+/Her2- and triple negative breast cancers.

Schmid P.  Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

The authors conclude that: Results suggest that adding pembrolizumab to neoadjuvant chemotherapy is beneficial for patients with the most aggressive disease and the highest unmet need. 

Gianni L, Huang C, Egle D, Bermejo B, et al.

The authors conclude that: xxxxpCR and safety data will be presented at the meeting. Patients will continue to be followed up to allow for assessing comparative long-term event-free and overall survival analyses.

Kevin Kalinsky, MD, MS
Columbia University Irving Medical Center
New York, NY

Turner N, Kingston B, Kilburn L, Kernaghan S, et al.

The authors conclude that: Circulating tumour DNA testing offers accurate tumour genotyping, sufficient for routine clinical practice. This approach can be used to identify patients with rare HER2 and AKT1 mutations, who have clinically relevant response rates with matched targeted therapies.

[GS3-07] The genomic landscape of breast cancer based on ctDNA analysis: data from the plasmaMATCH trial

Kingston B, Bye H, Hubank M, Walsh G, et al.

The authors conclude that: argeted ctDNA sequencing identified distinct genomic profiles of pre-treated advanced BC. ERBB2mutations are common in HER2 amplified advanced BC, with recurrent second novel mutations in PIK3CA common in HR+ BC.Targeted ctDNA sequencing identified distinct genomic profiles of pre-treated advanced BC. ERBB2mutations are common in HER2 amplified advanced BC, with recurrent second novel mutations in PIK3CA common in HR+ BC.

King TA, Liu MC, McClure MB, Hinoue T, et al.

The authors conclude that: Collection of banked primary and metastatic tissue pairs identified a young MBC cohort with a high frequency of breast cancer family history and second breast primaries. Molecular characterization of luminal tumor pairs highlighted acquisition of aggressive traits including increased proliferation and loss of differentiation in the metastases. In contrast, basal-like pairs remained relatively unchanged, except for the loss of immune activation. Ongoing analyses to be presented include clonal heterogeneity and phylogeny, novel metastasis signature discovery, gene fusion, and endogenous retrovirus detection.